Bridgebio Pharma SEC Filings

BridgeBio Pharma LLC, together with BridgeBio Pharma, Inc., reported acquiring 784,720 shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) common stock on 10/10/2025 under transaction code J.

The shares were issued pursuant to an amendment to the Transition Services Agreement dated August 11, 2025, in exchange for additional financial and accounting support services provided through December 31, 2025.

After the transaction, 14,589,846 shares were beneficially owned. The shares are held by BridgeBio Pharma LLC, with voting and investment power exercised by its parent, BridgeBio Pharma, Inc. The reporting persons and directors disclaim beneficial ownership except to any pecuniary interest. The reporting person is identified as a director, and the form was filed by more than one reporting person.

BridgeBio Pharma, Inc. (BBIO) reported insider sales by Chief Executive Officer and Director Neil Kumar under a Rule 10b5-1 plan. The filing shows multiple market sales on 10/08/2025 and 10/09/2025, totaling 223,090 shares disposed at weighted-average prices in the mid-$54 range. Shares sold were held indirectly through two trusts for which the reporting person is a co-trustee; the report disclaims beneficial ownership except for any pecuniary interest. The transactions were reported on a Form 4 and signed by an attorney-in-fact on 10/10/2025.

BridgeBio Pharma, Inc. (BBIO) submitted a Form 144 notice for a proposed sale of 120,000 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $6,506,400, scheduled approximately on 10/08/2025 and to be executed on NASDAQ. The shares were acquired on 03/26/2016 in a conversion of management incentive units. The filer disclosed multiple prior 10b5-1 sales over the past three months from related trusts and an individual, with individual trade sizes typically of 20,000 shares and one sale of 26,156 shares, generating proceeds in the $0.92M–$1.28M range per transaction.

The filing includes the standard Rule 144 representation that the seller does not possess undisclosed material adverse information and notes reliance on written trading plans where applicable.

BridgeBio Pharma, Inc. form 144 shows a proposed sale of 120,000 common shares with an aggregate market value of $6,506,400, to be executed approximately on 10/08/2025 on NASDAQ. The shares were acquired on 03/26/2016 via conversion of Management Incentive Units. The filing lists the total shares outstanding as 191,168,504. Recent disclosed transactions show multiple 10b5-1 sales by related trusts and an individual (including Kumar Haldea Revocable/Family Trusts and Neil Kumar) across 08/07/2025–09/05/2025, totaling 186,156 shares sold in the past three months. The filer certifies no undisclosed material adverse information and notes the 10b5-1 representation where applicable.

Frank McCormick, a director of BridgeBio Pharma, Inc. (BBIO), reported transactions dated 09/05/2025. On that date he exercised a stock option to acquire 74,000 shares at an exercise price of $11.92 per share. He also sold 74,000 shares with a weighted average sale price of $53.156 per share (range $52.96–$53.39). After the reported transactions the Form 4 shows 83,275 shares owned directly, 879,979 shares owned indirectly by the Francis P. McCormick Rev Trust, and 84,814 shares underlying options held directly.

BridgeBio Pharma director and CEO Neil Kumar reported planned sales under a Rule 10b5-1 plan adopted March 31, 2025. The Form 4 discloses multiple dispositions on September 4–5, 2025 totaling 223,090 shares sold of BridgeBio common stock at weighted-average prices in several ranges between about $50.52 and $53.91 per share. Following the reported transactions, the filing shows Kumar's indirect beneficial holdings via two trusts of 4,678,447 shares and 875,686 shares, respectively. The report was signed by an attorney-in-fact and states the reporting person disclaims beneficial ownership except for any pecuniary interest.

BridgeBio Pharma, Inc. (BBIO) Form 144 notice shows a proposed sale of 74,000 common shares through Morgan Stanley Smith Barney on 09/05/2025 for an aggregate market value of $3,932,056.60. The filing reports 191,168,504 shares outstanding and lists the exchange as NASDAQ. The shares to be sold were acquired on 09/05/2025 by stock option exercise from the issuer and paid for in cash.

The filing also discloses a prior sale by Frank P. McCormick of 100,000 common shares on 06/24/2025 producing gross proceeds of $4,422,800.00. The filer certifies they are unaware of undisclosed material adverse information about the issuer.

Thomas Trimarchi, President and Chief Financial Officer of BridgeBio Pharma, Inc. (BBIO), reported a sale of 42,237 shares of common stock on 08/21/2025 at a weighted-average price of $49.4846 per share (sales ranged from $49.08 to $49.77). After the transaction he beneficially owned 421,081 shares, reported as a direct holding. The Form 4 discloses the transaction code as a sale and includes an explanatory footnote that the reporting person can provide a breakdown of shares sold at each price within the stated range.

BridgeBio Pharma, Inc. (BBIO) director and CEO Neil Kumar reported insider sales under a Rule 10b5-1 plan. On 08/20/2025 the reporting person sold a total of 26,156 shares in two transactions (25,728 and 428 shares) at weighted average prices shown in the filing. Following those sales the filing reports 223,518 and 223,090 shares beneficially owned in the two reported lines, held directly. The report also discloses indirect holdings of 4,718,447 shares via the Kumar Haldea Revocable Trust and 915,686 shares via the Kumar Haldea Family Irrevocable Trust, of which the reporting person is a co-trustee. The transactions were effected pursuant to a 10b5-1 sales plan adopted March 31, 2025. The Form 4 was signed by an attorney-in-fact on 08/22/2025.